Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 11/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27196762 | 0.91 | RBP4 (0.43) | RBP4IDO1TDO2TRPV1HCRTR1 | |
| SCHEMBL30856724 | 0.91 | RBP4 (0.43) | RBP4IDO1TDO2TRPV1HCRTR1 | |
| SCHEMBL27196773 | 0.86 | RBP4 (0.40) | RBP4IDO1TDO2TRPV1HCRTR1 | |
| SCHEMBL30856720 | 0.86 | RBP4 (0.40) | RBP4IDO1TDO2TRPV1HCRTR1 | |
| SCHEMBL30857433 | 0.85 | NAMPT (0.44) | RBP4IDO1TDO2TRPV1 | |
| SCHEMBL29961897 | 0.76 | SSTR4 (0.42) | RBP4 | |
| SCHEMBL30305350 | 0.73 | RBP4 (0.48) | RBP4 | |
| SCHEMBL20744282 | 0.73 | RBP4 (0.48) | RBP4 | |
| SCHEMBL31608471 | 0.71 | HTR1A (0.43) | RBP4HCRTR1PDK2 | |
| SCHEMBL27196751 | 0.70 | RBP4 (0.41) | RBP4IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382282-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLYL DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2025-12-18 | — | — | US | disclosed |
| US-12398125-B2 | Nitrogen-containing saturated heterocyclyl derivative | Sumitomo Pharma Co., Ltd. (JP) | 2025-08-26 | — | — | US | disclosed |
| EP-4563574-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC RING DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2025-06-04 | — | — | EP | disclosed |
| US-20250051305-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLYL DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2025-02-13 | — | — | US | disclosed |
| US-12172987-B2 | Nitrogen-containing saturated heterocyclyl derivative | Sumitomo Pharma Co., Ltd. (JP) | 2024-12-24 | — | — | US | disclosed |
| US-20240124429-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLYL DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2024-04-18 | — | — | US | disclosed |
| WO-2024024962-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC RING DERIVATIVE | 住友ファーマ株式会社 | 2024-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382282-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLYL DERIVATIVE | H1-0, HTT, PRNP | RBP4 3913/4885IDO1 2884/4885TDO2 1828/4885 |
| US-12172987-B2 | Nitrogen-containing saturated heterocyclyl derivative | H1-0, HTT, PRNP | RBP4 3913/4885IDO1 2884/4885TDO2 1828/4885 |
| US-12398125-B2 | Nitrogen-containing saturated heterocyclyl derivative | H1-0, HTT, PRNP | RBP4 3913/4885IDO1 2884/4885TDO2 1828/4885 |
| US-20240124429-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLYL DERIVATIVE | H1-0, HTT, PRNP | RBP4 3913/4885IDO1 2884/4885TDO2 1828/4885 |
| US-20250051305-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLYL DERIVATIVE | H1-0, HTT, PRNP | RBP4 3913/4885IDO1 2884/4885TDO2 1828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.